[Skip to Content]
[Skip to Content Landing]

Screening for Chlamydia and GonorrheaUS Preventive Services Task Force Recommendation Statement

Educational Objective
To understand the benefits of screening for chlamydia and gonorrhea.
1 Credit CME
Abstract

Importance  Chlamydia and gonorrhea are among the most common sexually transmitted infections in the US. Infection rates are highest among adolescents and young adults of both sexes. Chlamydial and gonococcal infections in women are usually asymptomatic and may lead to pelvic inflammatory disease and its associated complications. Newborns of pregnant persons with untreated infection may develop neonatal chlamydial pneumonia or gonococcal or chlamydial ophthalmia. Infection in men may lead to urethritis and epididymitis. Both types of infection can increase risk of acquiring or transmitting HIV.

Objective  To update its 2014 recommendation, the US Preventive Services Task Force (USPSTF) commissioned a systematic review to evaluate the benefits and harms of screening for chlamydia and gonorrhea in sexually active adolescents and adults, including pregnant persons.

Population  Asymptomatic, sexually active adolescents and adults, including pregnant persons.

Evidence Assessment  The USPSTF concludes with moderate certainty that screening for chlamydia in all sexually active women 24 years or younger and in women 25 years or older who are at increased risk for infection has moderate net benefit. The USPSTF concludes with moderate certainty that screening for gonorrhea in all sexually active women 24 years or younger and in women 25 years or older who are at increased risk for infection has moderate net benefit. The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for chlamydia and gonorrhea in men.

Recommendation  The USPSTF recommends screening for chlamydia in all sexually active women 24 years or younger and in women 25 years or older who are at increased risk for infection. (B recommendation) The USPSTF recommends screening for gonorrhea in all sexually active women 24 years or younger and in women 25 years or older who are at increased risk for infection. (B recommendation) The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for chlamydia and gonorrhea in men. (I statement)

Sign in to take quiz and track your certificates

Buy This Activity

JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 Credit(s)™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC

CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.

Article Information

Corresponding Author: Karina W. Davidson, PhD, MASc, Feinstein Institutes for Medical Research at Northwell Health, 130 E 59th St, Ste 14C, New York, NY 10032 (chair@uspstf.net).

Accepted for Publication: August 4, 2021.

The US Preventive Services Task Force (USPSTF) members: Karina W. Davidson, PhD, MASc; Michael J. Barry, MD; Carol M. Mangione, MD, MSPH; Michael Cabana, MD, MA, MPH; Aaron B. Caughey, MD, PhD; Esa M. Davis, MD, MPH; Katrina E. Donahue, MD, MPH; Chyke A. Doubeni, MD, MPH; Alex H. Krist, MD, MPH; Martha Kubik, PhD, RN; Li Li, MD, PhD, MPH; Gbenga Ogedegbe, MD, MPH; Lori Pbert, PhD; Michael Silverstein, MD, MPH; Melissa A. Simon, MD, MPH; James Stevermer, MD, MSPH; Chien-Wen Tseng, MD, MPH, MSEE; John B. Wong, MD.

Affiliations of The US Preventive Services Task Force (USPSTF) members: Feinstein Institutes for Medical Research at Northwell Health, Manhasset, New York (Davidson); Harvard Medical School, Boston, Massachusetts (Barry); University of California, Los Angeles (Mangione); Albert Einstein College of Medicine, New York, New York (Cabana); Oregon Health & Science University, Portland (Caughey); University of Pittsburgh, Pittsburgh, Pennsylvania (Davis); University of North Carolina at Chapel Hill (Donahue); Mayo Clinic, Rochester, Minnesota (Doubeni); Fairfax Family Practice Residency, Fairfax, Virginia (Krist); Virginia Commonwealth University, Richmond (Krist); George Mason University, Fairfax, Virginia (Kubik); University of Virginia, Charlottesville (Li); New York University, New York, New York (Ogedegbe); University of Massachusetts Medical School, Worcester (Pbert); Boston University, Boston, Massachusetts (Silverstein); Northwestern University, Chicago, Illinois (Simon); University of Missouri, Columbia (Stevermer); University of Hawaii, Honolulu (Tseng); Pacific Health Research and Education Institute, Honolulu, Hawaii (Tseng); Tufts University School of Medicine, Boston, Massachusetts (Wong).

Author Contributions: Dr Davidson had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. The USPSTF members contributed equally to the recommendation statement.

Conflict of Interest Disclosures: Authors followed the policy regarding conflicts of interest described at https://www.uspreventiveservicestaskforce.org/Page/Name/conflict-of-interest-disclosures. All members of the USPSTF receive travel reimbursement and an honorarium for participating in USPSTF meetings.

Funding/Support: The USPSTF is an independent, voluntary body. The US Congress mandates that the Agency for Healthcare Research and Quality (AHRQ) support the operations of the US Preventive Services Task Force (USPSTF).

Role of the Funder/Sponsor: AHRQ staff assisted in the following: development and review of the research plan, commission of the systematic evidence review from an Evidence-based Practice Center, coordination of expert review and public comment of the draft evidence report and draft recommendation statement, and the writing and preparation of the final recommendation statement and its submission for publication. AHRQ staff had no role in the approval of the final recommendation statement or the decision to submit for publication.

Disclaimer: Recommendations made by the USPSTF are independent of the US government. They should not be construed as an official position of AHRQ or the US Department of Health and Human Services.

Additional Contributions: We thank Kathleen Irwin, MD, MPH (formerly of AHRQ), Tina Fan, MD, MPH (AHRQ), and Brandy Peaker, MD, MPH (AHRQ), who contributed to the writing of the manuscript, and Lisa Nicolella, MA (AHRQ), who assisted with coordination and editing.

Additional Information: The US Preventive Services Task Force USPSTF makes recommendations about the effectiveness of specific preventive care services for patients without obvious related signs or symptoms. It bases its recommendations on the evidence of both the benefits and harms of the service and an assessment of the balance. The USPSTF does not consider the costs of providing a service in this assessment. The USPSTF recognizes that clinical decisions involve more considerations than evidence alone. Clinicians should understand the evidence but individualize decision-making to the specific patient or situation. Similarly, the USPSTF notes that policy and coverage decisions involve considerations in addition to the evidence of clinical benefits and harms. Published by JAMA®–Journal of the American Medical Association under arrangement with the Agency for Healthcare Research and Quality (AHRQ). ©2021 AMA and United States Government, as represented by the Secretary of the Department of Health and Human Services (HHS), by assignment from the members of the United States Preventive Services Task Force (USPSTF). All rights reserved.

References
1.
Sexually transmitted disease surveillance 2019. Centers for Disease Control and Prevention. Reviewed 2021. Accessed July 28, 2021. https://www.cdc.gov/std/statistics/2019/default.htm
2.
Kreisel  KM , Spicknall  IH , Gargano  JW ,  et al.  Sexually transmitted infections among US women and men: prevalence and incidence estimates, 2018.   Sex Transm Dis. 2021;48(4):208-214. doi:10.1097/OLQ.0000000000001355PubMedGoogle ScholarCrossref
3.
Brunham  RC , Gottlieb  SL , Paavonen  J .  Pelvic inflammatory disease.   N Engl J Med. 2015;372(21):2039-2048. doi:10.1056/NEJMra1411426PubMedGoogle ScholarCrossref
4.
Farley  TA , Cohen  DA , Elkins  W .  Asymptomatic sexually transmitted diseases: the case for screening.   Prev Med. 2003;36(4):502-509. doi:10.1016/S0091-7435(02)00058-0PubMedGoogle ScholarCrossref
5.
Reekie  J , Donovan  B , Guy  R ,  et al; Chlamydia and Reproductive Health Outcome Investigators; Chlamydia and Reproductive Health Outcome Investigators.  Risk of pelvic inflammatory disease in relation to chlamydia and gonorrhea testing, repeat testing, and positivity: a population-based cohort study.   Clin Infect Dis. 2018;66(3):437-443. doi:10.1093/cid/cix769PubMedGoogle ScholarCrossref
6.
American Academy of Pediatrics. Prevention of neonatal ophthalmia. In: Kimberlin  DW , Brady  MT , Jackson  MA , eds.  Red Book: 2018 Report of the Committee on Infectious Diseases. 31st ed. American Academy of Pediatrics; 2018:1047-1102.
7.
Hammerschlag  MR .  Chlamydial and gonococcal infections in infants and children.   Clin Infect Dis. 2011;53(suppl 3):S99-S102. doi:10.1093/cid/cir699PubMedGoogle ScholarCrossref
8.
Stamm  WE . Chlamydia trachomatis infections of the adult. In: Holmes  K , ed.  Sexually Transmitted Disease. 4th ed. McGraw-Hill; 2008.
9.
Berger  RE , Alexander  ER , Monda  GD , Ansell  J , McCormick  G , Holmes  KK .  Chlamydia trachomatis as a cause of acute “idiopathic” epididymitis.   N Engl J Med. 1978;298(6):301-304. doi:10.1056/NEJM197802092980603PubMedGoogle ScholarCrossref
10.
Jacobs  NF , Kraus  SJ .  Gonococcal and nongonococcal urethritis in men: clinical and laboratory differentiation.   Ann Intern Med. 1975;82(1):7-12. doi:10.7326/0003-4819-82-1-7PubMedGoogle ScholarCrossref
11.
McConaghy  JR , Panchal  B .  Epididymitis: an overview.   Am Fam Physician. 2016;94(9):723-726.PubMedGoogle Scholar
12.
Korenromp  EL , Sudaryo  MK , de Vlas  SJ ,  et al.  What proportion of episodes of gonorrhoea and chlamydia becomes symptomatic?   Int J STD AIDS. 2002;13(2):91-101. doi:10.1258/0956462021924712PubMedGoogle ScholarCrossref
13.
Fleming  DT , Wasserheit  JN .  From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection.   Sex Transm Infect. 1999;75(1):3-17. doi:10.1136/sti.75.1.3PubMedGoogle ScholarCrossref
14.
Kalichman  SC , Pellowski  J , Turner  C .  Prevalence of sexually transmitted co-infections in people living with HIV/AIDS: systematic review with implications for using HIV treatments for prevention.   Sex Transm Infect. 2011;87(3):183-190. doi:10.1136/sti.2010.047514PubMedGoogle ScholarCrossref
15.
Procedure Manual. US Preventive Services Task Force. Published May 2021. Accessed July 28, 2021. https://uspreventiveservicestaskforce.org/uspstf/about-uspstf/methods-and-processes/procedure-manual
16.
Workowski  KA , Bachmann  LH , Chan  PA ,  et al.  Sexually transmitted infections treatment guidelines, 2021.   MMWR Recomm Rep. 2021;70(4):1-187. doi:10.15585/mmwr.rr7004a1PubMedGoogle ScholarCrossref
17.
Centers for Disease Control and Prevention.  Recommendations for the laboratory-based detection of Chlamydia trachomatis and Neisseria gonorrhoeae—2014.   MMWR Recomm Rep. 2014;63(RR-02):1-19.PubMedGoogle Scholar
18.
FDA clears first diagnostic tests for extragenital testing for chlamydia and gonorrhea. US Food and Drug Administration. Published May 23, 2019. Accessed July 28, 2021. https://www.fda.gov/news-events/press-announcements/fda-clears-first-diagnostic-tests-extragenital-testing-chlamydia-and-gonorrhea
19.
Cantor  A , Dana  T , Griffen  JC ,  et al.  Screening for Chlamydial and Gonococcal Infections: A Systematic Review Update for the US Preventive Services Task Force. Evidence Synthesis No. 206. Agency for Healthcare Research and Quality; 2021. AHRQ publication 21-05275-EF-1.
20.
St Cyr  S , Barbee  L , Workowski  KA ,  et al.  Update to CDC’s treatment guidelines for gonococcal infection, 2020.   MMWR Morb Mortal Wkly Rep. 2020;69(50):1911-1916. doi:10.15585/mmwr.mm6950a6PubMedGoogle ScholarCrossref
21.
Barrow  RY , Ahmed  F , Bolan  GA , Workowski  KA .  Recommendations for providing quality sexually transmitted diseases clinical services, 2020.   MMWR Recomm Rep. 2020;68(5):1-20. doi:10.15585/mmwr.rr6805a1PubMedGoogle ScholarCrossref
22.
Krist  AH , Davidson  KW , Mangione  CM ,  et al; US Preventive Services Task Force.  Screening for hepatitis B virus infection in adolescents and adults: US Preventive Services Task Force recommendation statement.   JAMA. 2020;324(23):2415-2422. doi:10.1001/jama.2020.22980PubMedGoogle Scholar
23.
Owens  DK , Davidson  KW , Krist  AH ,  et al; US Preventive Services Task Force.  Screening for hepatitis B virus infection in pregnant women: US Preventive Services Task Force reaffirmation recommendation statement.   JAMA. 2019;322(4):349-354. doi:10.1001/jama.2019.9365PubMedGoogle Scholar
24.
Owens  DK , Davidson  KW , Krist  AH ,  et al; US Preventive Services Task Force.  Screening for hepatitis C virus infection in adolescents and adults: US Preventive Services Task Force recommendation statement.   JAMA. 2020;323(10):970-975. doi:10.1001/jama.2020.1123PubMedGoogle Scholar
25.
Bibbins-Domingo  K , Grossman  DC , Curry  SJ ,  et al; US Preventive Services Task Force.  Serologic screening for genital herpes infection: US Preventive Services Task Force recommendation statement.   JAMA. 2016;316(23):2525-2530. doi:10.1001/jama.2016.16776PubMedGoogle Scholar
26.
Owens  DK , Davidson  KW , Krist  AH ,  et al; US Preventive Services Task Force.  Screening for HIV infection: US Preventive Services Task Force recommendation statement.   JAMA. 2019;321(23):2326-2336. doi:10.1001/jama.2019.6587PubMedGoogle Scholar
27.
Owens  DK , Davidson  KW , Krist  AH ,  et al; US Preventive Services Task Force.  Preexposure prophylaxis for the prevention of HIV infection: US Preventive Services Task Force recommendation statement.   JAMA. 2019;321(22):2203-2213. doi:10.1001/jama.2019.6390PubMedGoogle Scholar
28.
Bibbins-Domingo  K , Grossman  DC , Curry  SJ ,  et al; US Preventive Services Task Force (USPSTF).  Screening for syphilis infection in nonpregnant adults and adolescents: US Preventive Services Task Force recommendation statement.   JAMA. 2016;315(21):2321-2327. doi:10.1001/jama.2016.5824PubMedGoogle Scholar
29.
Curry  SJ , Krist  AH , Owens  DK ,  et al; US Preventive Services Task Force.  Screening for syphilis infection in pregnant women: US Preventive Services Task Force reaffirmation recommendation statement.   JAMA. 2018;320(9):911-917. doi:10.1001/jama.2018.11785PubMedGoogle Scholar
30.
Krist  AH , Davidson  KW , Mangione  CM ,  et al; US Preventive Services Task Force.  Behavioral counseling interventions to prevent sexually transmitted infections: US Preventive Services Task Force recommendation statement.   JAMA. 2020;324(7):674-681. doi:10.1001/jama.2020.13095PubMedGoogle Scholar
31.
Tao  G , Irwin  KL .  Receipt of HIV and STD testing services during routine general medical or gynecological examinations: variations by patient sexual risk behaviors.   Sex Transm Dis. 2008;35(2):167-171. doi:10.1097/OLQ.0b013e3181585be5PubMedGoogle ScholarCrossref
32.
Cantor  A , Dana  T , Griffen  JC ,  et al.  Screening for chlamydial and gonococcal infections: updated evidence report and systematic review for the US Preventive Services Task Force.   JAMA. Published September 14, 2021. doi:10.1001/jama.2021.10577Google Scholar
33.
LeFevre  ML ; US Preventive Services Task Force.  Screening for chlamydia and gonorrhea: US Preventive Services Task Force recommendation statement.   Ann Intern Med. 2014;161(12):902-910. doi:10.7326/M14-1981PubMedGoogle ScholarCrossref
34.
Falasinnu  T , Gilbert  M , Gustafson  P , Shoveller  J .  Deriving and validating a risk estimation tool for screening asymptomatic chlamydia and gonorrhea.   Sex Transm Dis. 2014;41(12):706-712. doi:10.1097/OLQ.0000000000000205PubMedGoogle ScholarCrossref
35.
Falasinnu  T , Gilbert  M , Gustafson  P , Shoveller  J .  A validation study of a clinical prediction rule for screening asymptomatic chlamydia and gonorrhoea infections among heterosexuals in British Columbia.   Sex Transm Infect. 2016;92(1):12-18. doi:10.1136/sextrans-2014-051992PubMedGoogle ScholarCrossref
36.
Falasinnu  T , Gilbert  M , Gustafson  P , Shoveller  J .  An assessment of population-based screening guidelines versus clinical prediction rules for chlamydia and gonorrhea case finding.   Prev Med. 2016;89:51-56. doi:10.1016/j.ypmed.2016.04.001PubMedGoogle ScholarCrossref
37.
Javanbakht  M , Westmoreland  D , Gorbach  P .  Factors associated with pharyngeal gonorrhea in young people: implications for prevention.   Sex Transm Dis. 2018;45(9):588-593. doi:10.1097/OLQ.0000000000000822PubMedGoogle ScholarCrossref
38.
Lavoué  V , Morcel  K , Voltzenlogel  MC ,  et al.  Scoring system avoids Chlamydia trachomatis overscreening in women seeking surgical abortions.   Sex Transm Dis. 2014;41(8):470-474. doi:10.1097/OLQ.0000000000000153PubMedGoogle ScholarCrossref
39.
Miller  WC , Hoffman  IF , Owen-O’Dowd  J ,  et al.  Selective screening for chlamydial infection: which criteria to use?   Am J Prev Med. 2000;18(2):115-122. doi:10.1016/S0749-3797(99)00146-4PubMedGoogle ScholarCrossref
40.
Berry  L , Stanley  B .  Comparison of self-collected meatal swabs with urine specimens for the diagnosis of Chlamydia trachomatis and Neisseria gonorrhoeae in men.   J Med Microbiol. 2017;66(2):134-136. doi:10.1099/jmm.0.000428PubMedGoogle ScholarCrossref
41.
Fang  J , Husman  C , DeSilva  L , Chang  R , Peralta  L .  Evaluation of self-collected vaginal swab, first void urine, and endocervical swab specimens for the detection of Chlamydia trachomatis and Neisseria gonorrhoeae in adolescent females.   J Pediatr Adolesc Gynecol. 2008;21(6):355-360. doi:10.1016/j.jpag.2008.03.010PubMedGoogle ScholarCrossref
42.
Nye  MB , Osiecki  J , Lewinski  M ,  et al.  Detection of Chlamydia trachomatis and Neisseria gonorrhoeae with the cobas CT/NG v2.0 test: performance compared with the BD ProbeTec CT Qx and GC Qx amplified DNA and Aptima AC2 assays.   Sex Transm Infect. 2019;95(2):87-93. doi:10.1136/sextrans-2018-053545PubMedGoogle ScholarCrossref
43.
Schachter  J , McCormack  WM , Chernesky  MA ,  et al.  Vaginal swabs are appropriate specimens for diagnosis of genital tract infection with Chlamydia trachomatis.   J Clin Microbiol. 2003;41(8):3784-3789. doi:10.1128/JCM.41.8.3784-3789.2003PubMedGoogle ScholarCrossref
44.
Schoeman  SA , Stewart  CM , Booth  RA , Smith  SD , Wilcox  MH , Wilson  JD .  Assessment of best single sample for finding chlamydia in women with and without symptoms: a diagnostic test study.   BMJ. 2012;345:e8013. doi:10.1136/bmj.e8013PubMedGoogle Scholar
45.
Shrier  LA , Dean  D , Klein  E , Harter  K , Rice  PA .  Limitations of screening tests for the detection of Chlamydia trachomatis in asymptomatic adolescent and young adult women.   Am J Obstet Gynecol. 2004;190(3):654-662. doi:10.1016/j.ajog.2003.09.063PubMedGoogle ScholarCrossref
46.
Skidmore  S , Kaye  M , Bayliss  D , Devendra  S .  Validation of COBAS Taqman CT for the detection of Chlamydia trachomatis in vulvo-vaginal swabs.   Sex Transm Infect. 2008;84(4):277-278. doi:10.1136/sti.2007.029587PubMedGoogle ScholarCrossref
47.
Stewart  CM , Schoeman  SA , Booth  RA , Smith  SD , Wilcox  MH , Wilson  JD .  Assessment of self taken swabs versus clinician taken swab cultures for diagnosing gonorrhoea in women: single centre, diagnostic accuracy study.   BMJ. 2012;345:e8107. doi:10.1136/bmj.e8107PubMedGoogle Scholar
48.
Sultan  B , White  JA , Fish  R ,  et al.  The “3 in 1” study: pooling self-taken pharyngeal, urethral, and rectal samples into a single sample for analysis for detection of Neisseria gonorrhoeae and Chlamydia trachomatis in men who have sex with men.   J Clin Microbiol. 2016;54(3):650-656. doi:10.1128/JCM.02460-15PubMedGoogle ScholarCrossref
49.
Oakeshott  P , Kerry  S , Aghaizu  A ,  et al.  Randomised controlled trial of screening for Chlamydia trachomatis to prevent pelvic inflammatory disease: the POPI (Prevention Of Pelvic Infection) trial.   BMJ. 2010;340:c1642. doi:10.1136/bmj.c1642PubMedGoogle ScholarCrossref
50.
Ostergaard  L , Andersen  B , Møller  JK , Olesen  F .  Home sampling versus conventional swab sampling for screening of Chlamydia trachomatis in women: a cluster-randomized 1-year follow-up study.   Clin Infect Dis. 2000;31(4):951-957. doi:10.1086/318139PubMedGoogle ScholarCrossref
51.
Scholes  D , Stergachis  A , Heidrich  FE , Andrilla  H , Holmes  KK , Stamm  WE .  Prevention of pelvic inflammatory disease by screening for cervical chlamydial infection.   N Engl J Med. 1996;334(21):1362-1366. doi:10.1056/NEJM199605233342103PubMedGoogle ScholarCrossref
52.
Hocking  JS , Temple-Smith  M , Guy  R ,  et al; ACCEPt Consortium.  Population effectiveness of opportunistic chlamydia testing in primary care in Australia: a cluster-randomised controlled trial.   Lancet. 2018;392(10156):1413-1422. doi:10.1016/S0140-6736(18)31816-6PubMedGoogle ScholarCrossref
53.
US Preventive Services Task Force. Screening for chlamydial infection—including ocular prophylaxis in newborns. In:  Guide to Clinical Preventive Services: Report of the US Preventive Services Task Force. 2nd ed. US Department of Health and Human Services; 1996.
54.
Ryan  GM  Jr , Abdella  TN , McNeeley  SG , Baselski  VS , Drummond  DE .  Chlamydia trachomatis infection in pregnancy and effect of treatment on outcome.   Am J Obstet Gynecol. 1990;162(1):34-39. doi:10.1016/0002-9378(90)90815-OPubMedGoogle ScholarCrossref
55.
US Preventive Services Task Force. Screening for gonorrhea—including ocular prophylaxis in newborns. In:  Guide to Clinical Preventive Services: Report of the US Preventive Services Task Force. 2nd ed. US Department of Health and Human Services; 1996.
56.
Chlamydia, gonorrhea, and syphilis. American college of obstetricians and gynecologists. Published January 2021. Accessed July 28, 2021. https://www.acog.org/womens-health/faqs/chlamydia-gonorrhea-and-syphilis
57.
Routine tests during pregnancy. American College of Obstetricians and Gynecologists. Updated July 2021. Accessed July 29, 2021. https://www.acog.org/womens-health/faqs/routine-tests-during-pregnancy
58.
Clinical Preventive Service Recommendation: sexually transmitted infections. American Academy of Family Physicians. Accessed July 28, 2021. https://www.aafp.org/family-physician/patient-care/clinical-recommendations/all-clinical-recommendations/stis.html
59.
Committee on Adolescence; Society for Adolescent Health and Medicine.  Screening for nonviral sexually transmitted infections in adolescents and young adults.   Pediatrics. 2014;134(1):e302-e311. doi:10.1542/peds.2014-1024PubMedGoogle ScholarCrossref
AMA CME Accreditation Information

Credit Designation Statement: The American Medical Association designates this Journal-based CME activity activity for a maximum of 1.00  AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to:

  • 1.00 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program;;
  • 1.00 Self-Assessment points in the American Board of Otolaryngology – Head and Neck Surgery’s (ABOHNS) Continuing Certification program;
  • 1.00 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program;
  • 1.00 Lifelong Learning points in the American Board of Pathology’s (ABPath) Continuing Certification program; and
  • 1.00 CME points in the American Board of Surgery’s (ABS) Continuing Certification program

It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting MOC credit.

Close
Want full access to the AMA Ed Hub?
After you sign up for AMA Membership, make sure you sign in or create a Physician account with the AMA in order to access all learning activities on the AMA Ed Hub
Buy this activity
Close
Want full access to the AMA Ed Hub?
After you sign up for AMA Membership, make sure you sign in or create a Physician account with the AMA in order to access all learning activities on the AMA Ed Hub
Buy this activity
Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close

Name Your Search

Save Search
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Close
Close

Lookup An Activity

or

My Saved Searches

You currently have no searches saved.

Close

My Saved Courses

You currently have no courses saved.

Close